Register
Login:
Share:
Email Facebook Twitter


EXCLUSIVE: Ascent Resources Operational Update & Review latest


Glaxosmithkline Share News (GSK)

Stock Market news at lse.co.uk - RSS News Feeds

Share News for Glaxosmithkline (GSK)


Share Price: 1,556.00Bid: 1,555.20Ask: 1,555.80Change: 0.00 (0.00%)No Movement on Glaxosmithkline
Spread: 0.60Spread as %: 0.04%Open: 1,575.80High: 1,584.20Low: 1,555.40Yesterday’s Close: 1,556.00






BUZZ-Mylan: Out of breath as delay feared for generic Advair

** Shares of Mylan NV down 4.4 pct to $39.83 in Thurs trading** Co late on Wed said U.S. health regulators were unable to approve its generic version
[14 Jun '18 15:17]

UPDATE 2-GSK's two-drug HIV treatment meets main goal in late stage studies

(Adds background on rival drugs, analyst comment, shares)June 14 (Reuters) - GlaxoSmithKline's two-drug treatment for HIV, the virus that causes AIDS,
[14 Jun '18 13:38]

UPDATE 3-UK stocks join European rally after ECB signals rate hike further away

* FTSE 100 up 0.8 pct* Unilever says Brazil strike hit sales, shares fall 3.7 pct* Restructuring, job cuts send Rolls Royce up 6.5 pct* Aveva jumps 12
[14 Jun '18 11:22]

UK stocks fall as monetary tightening spurs selloff

(For a live blog on European stocks, type LIVE/ in an Eikon news window)* FTSE 100 down 0.7 pct* Consumer staples lead losses as bond proxies suffer*
[14 Jun '18 10:09]

UPDATE 3-European shares rally after ECB pushes back rate hike bets

* STOXX 600 jump 1.4 pct* ECB to end bond buys, keep rates steady through next summer* Rolls Royce eyes savings, shares up (Updates prices, adds quote
[14 Jun '18 09:55]

European shares open lower before ECB meeting

MILAN, June 14 (Reuters) - European shares fell on Thursday in cautious trade after the U.S. Fed sounded slightly hawkish overnight and ahead of an EC
[14 Jun '18 08:03]

CORRECTED-UPDATE 1-GSK's two-drug HIV treatment meets main goal in late stage studies

(Corrects drug to lamivudine not rilpivirine and removes reference to once-daily tablet in paragraph 2, removes incorrect reference to aim of the stud
[14 Jun '18 07:46]

CORRECTED-GSK's two-drug HIV treatment meets main goal in late stage studies

(Removes incorrect reference to aim of the study in paragraph 2, corrects drug to lamivudine not rilpivirine and removes reference to once-daily table
[14 Jun '18 07:22]



Share Price, Share Chat, Stock Market news at lse.co.uk
FREE Member Services
- Setup a personalised Watchlist and Virtual Portfolio.
- Gain access to LIVE real-time Regulatory News (RNS).
- View more Trades, Directors' Deals, and Broker Ratings.
Share Price, Share Chat, Stock Market news at lse.co.uk






Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.